Navigation Links
Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Date:3/26/2009

BETHESDA, Md., March 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the Future Leaders in the Biotech Industry conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, April 2, 2009. A simultaneous webcast of the presentation will be available on the company's website at www.micromet-inc.com

    Forum:      Future Leaders in the Biotech Industry
    Date:       Thursday, April 2, 2009
    Time:       1:30 to 1:55 pm U.S. Eastern Time
    Place:      The Millennium Broadway Hotel & Conference Center
                New York City, New York
    Webcast:    www.micromet-inc.com

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 cli
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
2. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
3. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
4. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
5. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
6. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
7. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
8. Micromet to Present at the RBC Capital Markets Healthcare Conference
9. Micromet Added to NASDAQ Biotechnology Index
10. Micromet, Inc. Reports Third Quarter 2008 Financial Results
11. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 2015 Immunocore Limited, a ... treat cancer, viral infections and autoimmune disease, today ... Bell , the Regius Professor of Medicine at ... the Strategic Coordination of Health Research, to its ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/27/2015)... , 27. März 2015  Peter ... in Biomedical Science für seine bahnbrechende Arbeit ... zwischen Zellkompartimenten transportiert werden, sowie für die ... zur Reaktion auf Stress nutzen, der mit ... Walter ist Professor für Biochemie an der ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... China Medical Technologies, Inc.,(the "Company") (Nasdaq: ... company,that develops, manufactures and markets advanced in-vitro diagnostic ... development of two,proprietary molecular diagnostic kits for the ... patients with non-small cell lung,cancer ("NSCLC"). The Company ...
... Inc. (OTC Bulletin Board: SYMD) announced today that it ... bioresorbable membrane intended to prevent post-operative adhesions in nasal ... nasal and sinus procedures performed annually in the United ... Robert P. Hickey, SyntheMed,s President & CEO stated, "SinusShield ...
... November 25, ... ... https://www.atlanticabioenergy.com/ , ... ST.ANDREWS BY-THE-SEA, NB, Nov. 19 /PRNewswire/ - The global forestry industry is rapidly changing and it ...
Cached Biology Technology:China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits 2SyntheMed Announces FDA Clearance of SinusShield(TM) 2Media Advisory - Atlantica BioEnergy Task Force Leaders' Roundtable 2
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... A new surgical procedure for head and neck cancer ... accuracy for surgeons and reduced post-operative pain for patients. ... have shown it lessens the scarring, breathing problems and ... and neck cancers, said William Carroll, M.D., a scientist ...
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... Internationally respected scientists will gather next week for a ... a mind and to emphasize the need for $4 billion ... years. Presented by Great Ape Trust of Iowa, Decade ... recognized research pioneers from a variety of disciplines May 7-9 ...
Cached Biology News:New surgery improves head and neck cancer treatment 2Researchers discover molecular basis of a form of muscular dystrophy 2Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 2Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 3Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 4
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Mouse monoclonal antibody to DCAMKL2 - doublecortin and CaM kinase-like 2...
... new IKATUBE ULTRA TURRAX Tube Disperser System from ... system. It offers a cleaner, safer, and more ... processes sample volumes from 2 to 15 ml ... researchers can choose one of 4 different tube ...
... Wyatt Technology's family of light scattering instruments. ... temperature chromatograph and enables you to get ... The HTmD is easily installed in the ... Alliance 2000 device and enables you to ...
Biology Products: